IRIS UniCatt

Borghetti, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.604
EU - Europa 3.060
AS - Asia 2.775
SA - Sud America 658
AF - Africa 106
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 10.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.452
SG - Singapore 1.386
IT - Italia 746
CN - Cina 617
BR - Brasile 569
SE - Svezia 526
DE - Germania 413
FR - Francia 336
PL - Polonia 245
GB - Regno Unito 202
IE - Irlanda 150
VN - Vietnam 128
IN - India 117
FI - Finlandia 115
ID - Indonesia 99
CA - Canada 95
UA - Ucraina 65
RU - Federazione Russa 59
HK - Hong Kong 49
BD - Bangladesh 44
TR - Turchia 41
AR - Argentina 40
JP - Giappone 35
NL - Olanda 35
AT - Austria 33
BE - Belgio 32
MX - Messico 32
KR - Corea 30
IQ - Iraq 29
IR - Iran 27
ES - Italia 26
PK - Pakistan 26
SA - Arabia Saudita 26
AU - Australia 25
ZA - Sudafrica 25
CI - Costa d'Avorio 16
PH - Filippine 16
LT - Lituania 15
MA - Marocco 15
EG - Egitto 14
CH - Svizzera 12
MY - Malesia 12
VE - Venezuela 11
IL - Israele 10
CZ - Repubblica Ceca 9
EC - Ecuador 9
KE - Kenya 9
PY - Paraguay 9
UZ - Uzbekistan 9
CO - Colombia 8
NP - Nepal 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
TW - Taiwan 7
JO - Giordania 6
AL - Albania 5
CL - Cile 5
GR - Grecia 5
KG - Kirghizistan 5
LB - Libano 5
MD - Moldavia 5
NG - Nigeria 5
TH - Thailandia 5
AZ - Azerbaigian 4
BH - Bahrain 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EU - Europa 4
JM - Giamaica 4
OM - Oman 4
PA - Panama 4
PT - Portogallo 4
RO - Romania 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
KZ - Kazakistan 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PE - Perù 3
SD - Sudan 3
BG - Bulgaria 2
CM - Camerun 2
GE - Georgia 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MG - Madagascar 2
MM - Myanmar 2
MO - Macao, regione amministrativa speciale della Cina 2
PR - Porto Rico 2
QA - Qatar 2
VA - Santa Sede (Città del Vaticano) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
Totale 10.220
Salva come PNG Salva come JPEG
Città #
Singapore 704
Chandler 626
Ashburn 424
Kraków 209
New York 191
Milan 185
Rome 157
Dublin 147
Beijing 138
Los Angeles 115
Dallas 110
Jakarta 93
Hefei 89
San Mateo 79
Boston 67
Helsinki 66
Jacksonville 61
The Dalles 61
São Paulo 55
Chicago 53
Frankfurt am Main 52
Munich 52
Ann Arbor 48
Princeton 48
Wilmington 48
Ho Chi Minh City 44
Hong Kong 43
Marseille 42
Hanoi 35
London 35
Houston 34
Redmond 33
Tokyo 33
Nanjing 32
Moscow 30
Brooklyn 29
Brussels 29
Nuremberg 28
Denver 27
Lancaster 27
Seoul 27
Warsaw 27
Cattolica 26
Montreal 26
Santa Clara 26
Buffalo 25
Kent 25
Düsseldorf 24
Toronto 24
Vienna 23
Boardman 22
Amsterdam 21
Dearborn 20
Pune 20
Seattle 20
Atlanta 19
Fairfield 19
Rio de Janeiro 19
Turku 19
Roubaix 18
Lawrence 17
Poplar 17
Stockholm 17
Woodbridge 16
Abidjan 15
North Bergen 15
Portsmouth 15
Augusta 14
Belo Horizonte 14
Bremen 14
Lauterbourg 14
Manchester 14
Phoenix 14
Council Bluffs 13
Johannesburg 13
Redwood City 13
Chennai 12
Dammam 12
Lahore 12
Lappeenranta 12
Mexico City 12
Norwalk 12
Tianjin 12
Washington 12
Izmir 11
Kish 11
Nürnberg 11
Orem 11
Paris 11
Bexley 10
Dhaka 10
Ottawa 10
Andover 9
Cambridge 9
Guangzhou 9
Haiphong 9
Ankara 8
Baghdad 8
Cape Town 8
Changsha 8
Totale 5.313
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 496
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 249
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 210
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 206
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 205
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 199
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 194
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 188
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 180
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 177
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 174
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 171
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 170
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 158
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 150
Residual respiratory impairment after COVID-19 pneumonia 146
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 140
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 138
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 138
Residual respiratory impairment after COVID-19 pneumonia 137
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 136
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 134
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 128
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 128
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 127
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 126
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 126
Shall we dance? Extending tango's results to clinical practice 123
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 123
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 120
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 111
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 108
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 107
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 106
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 105
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 103
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 103
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 103
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 103
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 100
SARS-CoV-2 infection in a highly experienced person living with HIV 99
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 98
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 96
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 94
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 93
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 92
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 90
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 89
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 89
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 89
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 88
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 87
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 86
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 86
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 84
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 84
People Living with HIV in the COVID-19 Era: A Case Report 84
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 82
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 82
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 81
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 81
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 80
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 79
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 79
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 78
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 77
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 77
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 76
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 75
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 75
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 73
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 72
COVID-19 diagnosis does not rule out other concomitant diseases 72
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 71
People Living with HIV in the COVID-19 Era: A Case Report 70
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 70
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 70
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 69
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 69
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 68
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 68
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 67
Focal status epilepticus as unique clinical feature of COVID-19: A case report 65
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 63
Kaposi-like manifestations in a newly diagnosed aids transgendered patient with silicone embolism syndrome and disseminated tuberculosis 59
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 58
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 57
Real-life findings on the impact of the COVID-19 pandemic on HIV care 57
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 56
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 55
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 53
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 52
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 46
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 44
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 43
Totale 10.379
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021189 0 0 0 0 0 21 21 10 39 36 48 14
2021/2022714 35 21 16 74 20 23 65 116 31 56 89 168
2022/20232.059 212 261 180 330 209 273 85 156 220 54 60 19
2023/20241.121 43 227 36 100 62 183 77 30 39 54 136 134
2024/20252.263 29 54 262 87 176 93 147 115 300 187 469 344
2025/20263.022 733 175 353 712 988 61 0 0 0 0 0 0
Totale 10.379